Abstract: Diffuse large Bcell lymphoma (DLBCL) is a heterogeneous lymphoid malignancy and the most commonly occurring subtype of nonHodgkin's lymphoma (NHL)， with increasing incidence， which is great harmful to human health. More than 60% of DLBLC patients can be cured with standard RCHOP regimens， however， approximately 30% of patients will develop relapsed/refractory disease that remains a major cause of mortality. With recent advances in gene expression profiling， the indepth study of the molecular basis of chemotherapy resistance， optimization of salvage chemotherapy regimen， intervention of novel drugs and using chimeric antigen receptor Tcell therapy， and so on， these therapies might provide hope for individual accurate treatment of relapsed/refractory DLBCL. In this review， we focus on the progress of novel drugs and CART therapy in relapsed/refractory DLBCL.

Key words: lymphoma, Bcell, recurrence, receptors, antigen, Tcell, therapy